Navigation Links
JS Genetics Develops New Non-Invasive Test, XCAT-TS, to Help Doctors Diagnose Turner Syndrome

NEW HAVEN, Conn., March 3, 2011 /PRNewswire/ -- The launch of a new, non-invasive test for the identification of Turner syndrome (TS) was announced today by JS Genetics.  The test, XCAT-TS, is a simple cheek swab that identifies girls with Turner syndrome. Until now, Turner syndrome could only be diagnosed with a Karyotype, an invasive test that requires blood from the patient. The results of the XCAT-TS validation study were published in the February 2011 issue of Journal of Clinical Endocrinology & Metabolism.  

Turner syndrome, which affects females, is a chromosome problem in which all or part of one of the two X chromosomes is missing. Girls with Turner syndrome are short and can have other medical problems such as heart abnormalities, ovarian failure, delayed menstruation, mild hearing loss, non-verbal learning disability and others.

"The average age of diagnosis of Turner syndrome is about 11 years of age, which is unfortunate because early detection and treatment of TS leads to better outcomes," stated Dr. Scott Rivkees of Yale University, a pediatric endocrinologist and co-founder of JS Genetics. "Hopefully, this new, non-invasive test will lead to earlier recognition, earlier medical interventions, and improved outcomes for these girls."

XCAT-TS is a novel non-karyotype genetic test for the identification of Turner syndrome. The test's quantitative genotyping using proprietary markers spanning the X chromosome to detect loss of chromosome material allows for accurate identification of TS with clinically meaningful sensitivity and specificity in both Classic and Mosaic forms of Turner syndrome. In addition, the XCAT-TS test can detect Y chromosome material, which if present, is associated with a higher risk of ovarian tumors in TS patients.

For more information about JS Genetics, XCAT-TS and for physicians who would like to obtain a kit at no charge, visit

About JS Genetics

JS Genetics Inc., a private company, develops and markets proprietary, high value DNA diagnostic tests for medical conditions in newborns, children, and adolescents.  In the past 4 years, JS Genetics has been awarded 4 Phase I and 3 Phase II Small Business Innovation Research (SBIR) grants from the National Institutes of Health.  The company's strategy is to develop tests using cheek swabs for sample collection on a PCR based testing platform to bring to market accurate, convenient and scalable DNA diagnostics.  

Other tests currently under development include:

  • Non-Karyotype cheek swab test for detection of Klinefelter Syndrome
  • Non-Karyotype test for detection of Down Syndrome
  • Cheek swab test for Dyslexia predisposition
  • Non-Southern Blot, cheek swab test for detection of Fragile X Syndrome

All test are developed and performed in our CLIA certified (ID# 07D1091103) and CAP accredited (CAP# 72115351) laboratory in New Haven CT.

SOURCE JS Genetics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Genetics Determine Optimal Drug Dose of Common Anticoagulant
4. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
5. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
6. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
7. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
8. deCODE Obesity Study Sheds Light on How Genetics Affects Risk and Onset of Common Diseases
9. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
10. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
11. CellCyte Genetics Signs Collaborative Agreement With Northwestern Universitys Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCytes CCG-TH30 Product Candidate
Post Your Comments:
(Date:10/4/2017)... , Oct. 4, 2017 OBP ... self-contained, illuminating medical devices, today announced regulatory approval ... Surveillance Agency (or Agência Nacional de Vigilância Sanitária ... single-use, cordless surgical retractor with integrated LED light ... access, illumination and exposure of a tissue pocket ...
(Date:10/2/2017)... INDIANAPOLIS , Oct. 2, 2017  Eli Lilly ... its financial results for the third quarter of 2017 ... a conference call on that day with the investment ... performance. The conference call will begin at ... public can access a live webcast of the conference ...
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the European ... system called the HORIZON at MIBio 2017 in Cambridge, ... and visible particulate matter in biopharmaceutical samples with unprecedented speed and ... the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
Breaking Medicine News(10 mins):